Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage
The former Novartis Oncology CEO will oversee the FDA approval and launch of UroGen's lead asset, UGN-101, for low-grade upper tract urothelial cancer, and build out the company's longer-term strategy. Scrip talked to Barrett about the transition from big pharma leadership to the CEO of a small biopharma.
You may also be interested in...
Jelmyto relies on a proprietary sustained-release drug delivery technology that UroGen plans to use for future drugs. The company is moving ahead with a launch in June, relying on virtual technology.
The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.